Device Trial Radar · NCT07298473
Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Apr 8, 2026
Primary completion
Mar 29, 2028
Study completion Mar 29, 2028
Sponsor
- Lead sponsor
- Medtronic Cardiac Ablation SolutionsPublic (MDT)
- Sponsor type
- Industry
- First posted
- Dec 23, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Conquer-AF is a prospective, multi-center, interventional, non-randomized clinical study that will enroll up to 400 subjects at up to 30 sites across the United States, Europe, and Australia. Subjects diagnosed with symptomatic recurrent paroxysmal or persistent atrial fibrillation after a single prior ablation procedure will be enrolled in this study. Each subject will undergo a study index redo ablation procedure using the Sphere-9 Catheter and Affera Ablation System and will be followed for 12 months. The expected total study duration (from time of first enrollment to the exit of last enrolled subject) is approximately 2 years.
Conditions
- Atrial Fibrillation (AF)
- Persistent Atrial Fibrillation
- Paroxysmal Atrial Fibrillation (PAF)
Interventions
Sphere-9 Catheter AblationDevice
Redo atrial fibrillation ablation performed using the Sphere-9 Catheter in conjunction with the Affera Ablation System and Affera Mapping System. The intervention delivers radiofrequency and pulsed field energy according to the study protocol for treatment of recurrent paroxysmal or persistent AF. All participants receive this device-based ablation procedure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effectiveness: Number of Participants With Treatment Success.Time frame: 12-months post-redo ablation procedure
- Safety: Number of Participants With at Least One Primary Safety EventTime frame: 6-months post-redo ablation procedure
Locations
30 sites in 6 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham (UAB) Hospital
Birmingham, Alabama · Recruiting
Scripps Green Hospital
La Jolla, California · Not yet recruiting
Cedars Sinai Medical Center
Los Angeles, California · Recruiting
27 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.